Andrea Rubbert‐Roth

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma et al. · Annals of the Rheumatic Diseases · 2020 · 2.6K citations · Full text

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld et al. · Annals of the Rheumatic Diseases · 2013 · 1.8K citations · Full text

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.6K citations · Full text

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Josef S Smolen, André Beaulieu, Andrea Rubbert‐Roth et al. · The Lancet · 2008 · 1.4K citations

Inflammation, Rheumatology, Rheumatoid Disorder +10

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Mark C. Genovese, Roy Fleischmann, Bernard Combe et al. · The Lancet · 2018 · 415 citations

Rheumatoid Disorder, Rheumatology, Anti-inflammatory +9